Tumor necrosis factor alpha-induced protein 8-like protein 3 (TNFAIP8L3)

Tumor necrosis factor alpha-induced protein 8-like protein 3 (TNFAIP8L3, also known as TIPE3) is a cytosolic lipid transfer protein belonging to the TIPE (TNFAIP8) family[1][4][5]. TIPE3 is characterized structurally by a unique hydrophobic cavity that facilitates the selective binding and shuttling of lipid second messengers, especially phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3), to the plasma membrane[1][4][5]. Through this lipid transfer activity, TIPE3 amplifies phosphoinositide signaling, enhancing the PI3K–AKT and MEK–ERK signaling pathways, which are critical regulators of cell proliferation, migration, and survival[1][3][4][5]. TIPE3 is most highly expressed in secretory epithelial tissues and its upregulation has been implicated in a broad range of cancers, where it promotes tumor growth, invasion, metastasis, and possibly contributes to chemotherapy resistance[3]. TIPE3 thus represents an emerging molecular target for therapeutic intervention and a potential biomarker for tumor aggressiveness, although no drugs currently target this protein directly[1][3][4][5].

Other names

TNFAIP8L3Tumor necrosis factor alpha-induced protein 8-like protein 3TNFAIP8-like protein 3TIPE3FLJ41287TP8L3Tumor necrosis factor, alpha-induced protein 8-like 3

Drugs would be expected to modulate activity by influencing phosphoinositide signaling (PI3K–AKT, MEK–ERK pathway), though none are currently noted as clinically validated in this context[1][3][4].